ImmunoPET: concept, design, and applications

W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Click chemistry and radiochemistry: an update

D Bauer, MA Cornejo, TT Hoang, JS Lewis… - Bioconjugate …, 2023 - ACS Publications
The term “click chemistry” describes a class of organic transformations that were developed
to make chemical synthesis simpler and easier, in essence allowing chemists to combine …

Precision modification of native antibodies

KL Wu, C Yu, C Lee, C Zuo, ZT Ball… - Bioconjugate …, 2021 - ACS Publications
Antibodies, particularly of the immunoglobulin G (IgG) isotype, are a group of biomolecules
that are extensively used as affinity reagents for many applications in research, disease …

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis

F Krutzek, K Kopka, S Stadlbauer - Pharmaceuticals, 2022 - mdpi.com
Immune checkpoint inhibitor (ICI) therapy has emerged as a major treatment option for a
variety of cancers. Among the immune checkpoints addressed, the programmed death …

Quantifying PD-L1 expression to monitor immune checkpoint therapy: opportunities and challenges

S Nimmagadda - Cancers, 2020 - mdpi.com
Simple Summary Malignant cells hijack the regulatory roles of immune checkpoint proteins
for immune evasion and survival. Therapeutics blocking those proteins can restore the …

The future of cancer diagnosis, treatment and surveillance: a systemic review on immunotherapy and immuno-pet radiotracers

V Liberini, R Laudicella, M Capozza, MW Huellner… - Molecules, 2021 - mdpi.com
Immunotherapy is an effective therapeutic option for several cancers. In the last years, the
introduction of checkpoint inhibitors (ICIs) has shifted the therapeutic landscape in oncology …

Noninvasive Imaging of Tumor PD-L1 Expression Using [99mTc]Tc-Labeled KN035 with SPECT/CT

Y Zhang, Y Ding, N Li, S Wang, S Zhou… - Molecular …, 2022 - ACS Publications
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) checkpoint blockade is a major
breakthrough in cancer therapy, but identifying patients likely to benefit from this therapy …

[HTML][HTML] Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer

Y Chen, S Zhu, J Fu, J Lin, Y Sun, G Lv, M Xie… - Journal of …, 2022 - Elsevier
Despite advances in immunotherapy for the treatment of cancers, not all patients can benefit
from programmed cell death ligand 1 (PD-L1) immune checkpoint blockade therapy. Anti-PD …

[HTML][HTML] Molecular immune targeted imaging of tumor microenvironment

T Rakhshandehroo, BR Smith, HJ Glockner… - …, 2022 - ncbi.nlm.nih.gov
Novel targeted therapies are rapidly emerging for the treatment of cancer. With the advent of
new immune targeting agents, understanding the changes in the tumor microenvironment …

[HTML][HTML] Refining patient selection for breast cancer immunotherapy: beyond PD-L1

M Kossai, N Radosevic-Robin, F Penault-Llorca - ESMO open, 2021 - Elsevier
Therapies that modulate immune response to cancer, such as immune checkpoint inhibitors,
began an intense development a few years ago; however, in breast cancer (BC), the results …